lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Follow-Up of Multi-Organ Dysfunction and Inflammation Using Biomarker Kinetics in Patients with Severe COVID-19 Disease and Association with Disease Outcomes: Results from a Referral Center Cohort in the North East of France

54 Pages Posted: 8 Jun 2020

See all articles by Abderrahim Oussalah

Abderrahim Oussalah

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics; University of Lorraine - INSERM UMR_S 1256

Stanislas Gleye

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Isabelle Clerc Urmes

University of Lorraine - University Hospital of Nancy - Department of Methodology

Elodie Laugel

University of Lorraine - Nancy-Université

Françoise Barbé

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Sophie Orlowski

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Catherine Malaplate

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Isabelle Aimone-Gastin

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Beatrice Maatem Caillierez

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Marc Merten

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Elise Jeannesson

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Raphaël Kormann

University of Lorraine - University Hospital of Nancy - Department of Nephrology

Jean-Luc Olivier

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Rosa-Maria Rodriguez-Guéan

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Farès Namour

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Sybille Bevilacqua

University of Lorraine - University Hospital of Nancy - Department of Infectious Diseases

Nathalie Thilly

University of Lorraine - University Hospital of Nancy - Department of Methodology, Promotion and Investigation

Marie-Reine Losser

University of Lorraine - University Hospital of Nancy - Department of Anesthesiology and Intensive Care Medicine

Antoine Kimmoun

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Luc Frimat

University of Lorraine - University Hospital of Nancy - Department of Nephrology

Bruno Levy

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Sébastien Gibot

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Evelyne Schvoerer

CHRU de Nancy Brabois - Laboratoire de Virologie

Jean-Louis Gueant

University of Lorraine - Nutrition, Genetics, and Environmental Risk Exposure (NGERE); University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics; University of Lorraine - Reference Centre for Inborn Errors of Metabolism (ORPHA67872)

More...

Abstract

BACKGROUND: COVID-19 disease can induce pulmonary and systemic inflammation and subsequent multi-organ dysfunction. In patients with severe COVID-19 disease, no data are available on the follow-up of multi-organ dysfunction and inflammation by assessing the kinetics of biochemical biomarkers and its association with disease-related complications.

METHODS: We carried out a retrospective, longitudinal cohort study on all newly diagnosed consecutive patients among the first cases of severe COVID-19 disease that required hospitalization at the University Hospital of Nancy from March 1, 2020, to March 25, 2020. The final date of follow-up was March 31, 2020. The primary aim was to assess the occurrence of multi-organ dysfunction (kidney, lung, heart, liver, muscle) and inflammation as evaluated by biomarker kinetics in patients with severe COVID-19 disease. The secondary aims were to assess the association between biomarkers variation and the occurrence of COVID-19 related acute respiratory failure (ARF) and death. We estimated the kinetics over time of the biochemical markers using the isotonic regression method. We used a multistep approach to assess the association between the occurrence of kidney, lung, heart, and liver dysfunctions and inflammation as evaluated by biomarker kinetics and the occurrence of the secondary endpoints (ARF, death). Bivariate analyses were performed using receiver operating characteristic (ROC) analysis and time-series analyses. To look for independent predictors, we performed multivariable multilevel analysis using two-level hierarchical logistic models.

FINDINGS: A total of 162 patients were assessed. During the study period, 1151 biochemical explorations were carried out for up to 59 biochemical markers, totaling 15,260 biochemical values. The most frequently observed biochemical abnormalities during the follow-up (≥25% of the observed time) were increased urea nitrogen, hyperosmolality, hypocalcemia, low hemoglobin, and hypoxemia; major cytolysis with severe cholestatic syndromes and conjugated hyperbilirubinemia; increased C-reactive protein (CRP); increased troponin, N-Terminal pro-Brain Natriuretic Peptide, and muscle markers; and hypoalbuminemia with hypertriglyceridemia. The evolution of phosphorus followed a biphasic curve with a decrease during the first four days, followed by a progressive increase in parallel with urea nitrogen and creatinine. The proportion of patients who developed an acute kidney injury (AKI) stage 3, increased significantly over time (0·9%, day 0; 21·4%, day 14; P <0·001). In the multivariable multilevel analysis, three variables were independently associated with the risk of ARF: CRP >90 mg/L (odds ratio [OR] 6·87, 95% CI, 2·36–20·01), urea nitrogen >0·36 g/L (OR 3·91, 95% CI, 1·15–13·29), and type 2 diabetes (OR 4·49, 95% CI, 1·07–18·89). In bivariate analyses, urea nitrogen >0·42 g/L, but not CRP, was associated with the risk of COVID-19 related death.

INTERPRETATION: In this retrospective, longitudinal cohort study using an extensive biochemical dataset on consecutive patients with newly diagnosed severe COVID-19 disease, the follow-up of biochemical biomarkers kinetics was consistent with a severe multi-organ involvement along with a severe acute inflammatory response. Our study pointed out new biochemical abnormalities targeting other organs than lungs and kidneys, including the liver and biliary tract with marked cholestatic syndromes. High levels of CRP and urea nitrogen were potential predictors of ARF among patients with severe COVID-19 disease. Further studies should address the significance of acute kidney injury in the prediction of COVID-19 related death.

FUNDING STATEMENT: None.

DECLARATION OF INTERESTS: The authors who have taken part in this study declare that they do not have anything to disclose regarding conflicts of interest concerning this manuscript.

ETHICS APPROVAL STATEMENT: The “Nancy Biochemical Database” is registered at the French National Commission on Informatics and Liberty, CNIL, under the record N°1763197v0. The Ethics committee of the University Hospital of Nancy approved the study (ID: 2020/264).

Keywords: COVID-19 Disease; SARS-CoV-2; Biomarker Kinetics; Multi-organ involvement; Disease outcomes; Big data approach

Suggested Citation

Oussalah, Abderrahim and Gleye, Stanislas and Urmes, Isabelle Clerc and Laugel, Elodie and Barbé, Françoise and Orlowski, Sophie and Malaplate, Catherine and Aimone-Gastin, Isabelle and Caillierez, Beatrice Maatem and Merten, Marc and Jeannesson, Elise and Kormann, Raphaël and Olivier, Jean-Luc and Rodriguez-Guéan, Rosa-Maria and Namour, Farès and Bevilacqua, Sybille and Thilly, Nathalie and Losser, Marie-Reine and Kimmoun, Antoine and Frimat, Luc and Levy, Bruno and Gibot, Sébastien and Schvoerer, Evelyne and Gueant, Jean-Louis, Follow-Up of Multi-Organ Dysfunction and Inflammation Using Biomarker Kinetics in Patients with Severe COVID-19 Disease and Association with Disease Outcomes: Results from a Referral Center Cohort in the North East of France (4/29/2020). Available at SSRN: https://ssrn.com/abstract=3590489 or http://dx.doi.org/10.2139/ssrn.3590489

Abderrahim Oussalah (Contact Author)

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics ( email )

Nancy, F-54000
France
+33 3 83 68 32 92 (Phone)
+33 3 83 15 35 91 (Fax)

University of Lorraine - INSERM UMR_S 1256

Nancy, F-54000
France

Stanislas Gleye

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Isabelle Clerc Urmes

University of Lorraine - University Hospital of Nancy - Department of Methodology

Nancy, F-54000
France

Elodie Laugel

University of Lorraine - Nancy-Université

France

Françoise Barbé

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Sophie Orlowski

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Catherine Malaplate

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Isabelle Aimone-Gastin

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Beatrice Maatem Caillierez

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Marc Merten

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Elise Jeannesson

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Raphaël Kormann

University of Lorraine - University Hospital of Nancy - Department of Nephrology

Nancy, F-54000
France

Jean-Luc Olivier

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Rosa-Maria Rodriguez-Guéan

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Farès Namour

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics

Nancy, F-54000
France

Sybille Bevilacqua

University of Lorraine - University Hospital of Nancy - Department of Infectious Diseases

Nancy, F-54000
France

Nathalie Thilly

University of Lorraine - University Hospital of Nancy - Department of Methodology, Promotion and Investigation

Nancy, F-54000
France

Marie-Reine Losser

University of Lorraine - University Hospital of Nancy - Department of Anesthesiology and Intensive Care Medicine

Nancy, F-54000
France

Antoine Kimmoun

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Nancy, F-54000
France

Luc Frimat

University of Lorraine - University Hospital of Nancy - Department of Nephrology

Nancy, F-54000
France

Bruno Levy

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Nancy, F-54000
France

Sébastien Gibot

University of Lorraine - University Hospital of Nancy - Medical Intensive Care Unit

Nancy, F-54000
France

Evelyne Schvoerer

CHRU de Nancy Brabois - Laboratoire de Virologie

France

Jean-Louis Gueant

University of Lorraine - Nutrition, Genetics, and Environmental Risk Exposure (NGERE) ( email )

Nancy
France

University of Lorraine - Department of Molecular Medicine and Personalized Therapeutics ( email )

Nancy, F-54000
France

University of Lorraine - Reference Centre for Inborn Errors of Metabolism (ORPHA67872) ( email )

Nancy, F-54000
France